26 results
8-K
EX-99.1
XFOR
X4 Pharmaceuticals Inc
21 Mar 24
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial
7:43am
mavorixafor be approved for WHIM syndrome in the U.S.
Research and Development (R&D) Expenses were $15.3 million and $72.0 million for the fourth … quarter and full year ended December 31, 2023, respectively, as compared to $19.0 million and $61.1 million for the comparable periods in 2022. R&D expenses
8-K
EX-99.1
XFOR
X4 Pharmaceuticals Inc
9 Nov 23
X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates
8:07am
in the U.S.
Research and Development (R&D) Expenses were $19.1 million for the third quarter ended September 30, 2023 as compared to $14.1 million … for the comparable period in 2022. R&D expenses for the third quarter ended September 30, 2023 included $1.3 million of certain non-cash expenses.
Selling
8-K
EX-99.1
XFOR
X4 Pharmaceuticals Inc
18 Oct 23
X4 Pharmaceuticals Announces Appointment of Industry Veteran R. Keith Woods to Board of Directors
8:17am
transition from an R&D organization to a global commercial organization. Following his retirement from argenx, Mr. Woods continues to serve as an advisor
8-K
EX-99.1
XFOR
X4 Pharmaceuticals Inc
10 Aug 23
Provides Corporate Updates, and Reports Emerging Data from
6:41am
for WHIM syndrome in the U.S.
Research and Development (R&D) Expenses were $15.6 million for the second quarter ended June 30, 2023 as compared … to $13.8 million for the comparable period in 2022. R&D expenses for the second quarter ended June 30, 2023 included $1.1 million of certain non-cash
8-K
EX-99.1
XFOR
X4 Pharmaceuticals Inc
4 May 23
X4 Pharmaceuticals Reports First-Quarter 2023 Financial
9:05am
to support company operations into the second quarter of 2024.
Research and Development (R&D) Expenses were $22.1 million for the first quarter ended … March 31, 2023 as compared to $14.1 million for the comparable period in 2022. R&D expenses for the first quarter ended March 31, 2023 included $0.8
8-K
EX-99.1
9izvw986s gez
4 May 23
X4 Pharmaceuticals Reports First-Quarter 2023 Financial
6:42am
8-K
EX-99.1
g72g0g0
3 Nov 22
X4 Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
7:21am
8-K
EX-99.1
zco1q tv249
4 Oct 22
Regulation FD Disclosure
4:42pm
8-K
EX-99.1
8d1xs2molusxl85 98
5 Aug 22
Regulation FD Disclosure
8:10am
8-K
EX-99.1
wfd8 946v4pxl
4 Aug 22
X4 Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
7:29am
8-K
EX-99.1
vf6n2v7 6l8
12 May 22
X4 Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
8:00am
8-K
EX-99.1
lhctk6
17 Mar 22
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
8:23am
8-K
EX-99.1
0pbyb4ph qydnzyvz6z
4 Nov 21
Results of Operations and Financial Condition
9:01am
8-K
EX-99.1
qi8ek3
3 Aug 21
X4 Pharmaceuticals Announces Key Enrollment Milestone Achievements in Ongoing Mavorixafor Clinical Trials and Reports Second Quarter
8:12am
8-K
EX-99.1
xxznkwxdy
6 May 21
X4 Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update
8:13am
8-K
EX-99.1
aykkaavs5ka huxg
4 Mar 21
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
8:23am
8-K
EX-99.1
esav0k0
5 Nov 20
X4 Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
8:13am
8-K
EX-99.1
45szqa6e bjcqf3qwnq
7 Nov 19
X4 Pharmaceuticals Reports Third Quarter 2019 Financial Results and Recent Business Highlights
7:10am
8-K
s70sp1 pk8c7bv94
2 Apr 19
Departure of Directors or Certain Officers
8:37am